Integration of HIV services – what does that really mean?
Lenacapavir PrEP ‘special cases’: young people, missed doses and drug interactions
The funding scramble: countries desperately seek HIV finance solutions
Is HIV integration a response or a death sentence? Communities demand answers
Does six-monthly PrEP have a future following the collapse of global HIV funding?
Stepping into the AI-driven future of HIV prevention and care
Children born with HIV have persistent inflammation markers linked to heart disease
The US cuts challenge African funders and governments to provide new models of PrEP access
Conflicts and humanitarian crises create new HIV vulnerabilities
US funding cuts cause immediate drops in numbers testing and on HIV treatment
Broadly neutralising antibodies plus immune modulator may delay HIV rebound
Lenacapavir and cabotegravir PrEP supported for use in pregnancy and breastfeeding
Injectable HIV treatment works for people with poor HIV control in Africa
Intermittent HIV treatment dosing may be a response to the funding crisis, but adolescent study raises concerns
Scaling back PEPFAR will leave 700,000 without PrEP and cause 6700 new HIV infections within a year
Treatment changes do not reduce weight in people with HIV
Once-monthly oral PrEP moves into late-stage trials
Engineered T-cells may kill off reservoir cells, mimicking elusive CD8 vaccine effect
